Abstract
Previously the biology of lung cancer was only of the researcher's interest. The discovery of EGFR mutations revolutionized the strategy of lung cancer treatment with customized therapies based on the detection of molecular abnormalities in driver oncogenes to select patients who could benefit of targeted treatment. Currently, EGFR mutations and ALK gene rearrangements are the only biomarker analyses that are recommended based on efficient therapies existing against tumours presenting these abnormalities. In the near future, other driver oncogenes and targeted treatment against them will be discovered and implemented in clinic in the treatment of lung cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
